HBV
Conditions
Interventions
NAs:entecavir (ETV)/tenofovir disoproxil fumarate (TDF)/tenofovir alafenamid fumarate (TAF)
NAs sequential/combined Peg IFN a:entecavir (ETV)/tenofovir disoproxil fumarate (TDF)/tenofovir alafenamid fumarate (TAF)sequential/combined Peg IFN a (180ug SC qw for weight ? 75kg, 135ug SC qw for <
Sponsors
Beijing Youan Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age: ?18 years old, no gender; It meets the diagnostic criteria for chronic HBV infection established in the Guidelines for Prevention and Treatment of Chronic Hepatitis B in China (2019 edition). HBeAg positive, HBV DNA > 2×104IU/ml; ALT=1 x ULN (ULN 40U/L); The patient had not received prior antiviral therapy (including nucleoside analogues and interferon therapy); Liver biopsy has been performed in our hospital to confirm that the patient is in the immune tolerance period.
Exclusion criteria
Exclusion criteria: Cirrhosis of the liver. Diagnosis or suspected hepatocellular carcinoma; Patients with other viral infections, such as chronic hepatitis C, hepatitis A, hepatitis D and other heparotropic viruses; The patient had other liver diseases, such as liver malignancy, alcoholic liver disease, autoimmune liver disease, hemochromatosis, drug-induced hepatitis, and hepatolenticular degeneration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VR at week48;48-week HBeAg seroconversion;Decrease level of HBeAg in 48 weeks; | — |
Countries
China
Contacts
Public ContactRenshan
Beijing Youan Hospital, Capital Medical University
Outcome results
None listed